Olga Dontsova is a Full Professor at Moscow State University (MSU) in the Faculty of Chemistry. She serves as Head of the Division of RNA Structure and Function at the Belozersky Institute of Physico-Chemical Biology and Head of the Chair of Chemistry of Natural Compounds. Her research spans molecular biology, bioorganic chemistry, and RNA-based mechanisms. Research Focus: She investigates structure-functional relationships in ribonucleoprotein complexes, with emphasis on translation machinery, transfer-messenger RNA (tmRNA) interactions with ribosomes, RNA methyltransferases, and telomerase's role in cancer. Her team pioneered a chemical-biochemical-genetic approach to map mRNA topography in ribosomes, elucidate trans-translation dynamics, and characterize novel RNA-modifying enzymes. Scientific Contributions: Developed a molecular dynamic model for trans-translation Discovered unique yeast telomerase with unconventional properties Investigated functional roles of modified RNA residues in translation Honors: Member of Academia Europaea (2014) Corresponding Member of Russian Academy of Sciences (2006) European Academy Award for Young Scientists (1994) Grants & Leadership: Her work has been funded by HHMI, HFSP, CRDF, INTAS, RFFI, and Russian Ministry of Science and Education. She chairs the Biology Panel of the Russian Scientific Foundation and serves on editorial boards for Biochimie, Russian Journal of Molecular Biology, and Acta Naturae. Teaching: As a supervisor of 21 Ph.D. students and numerous diploma projects, she teaches advanced courses at MSU while maintaining an active research program.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Christian Friedrich Wilhelm Becker is a full Professor at the University of Vienna, holding a position within the Faculty of Chemistry and the Department of Biological Chemistry. His research profile shows extensive activity in protein chemistry and biochemistry, with particular focus on post-translational modifications and their implications in disease mechanisms. His work bridges chemical biology, biochemistry, and biomedical applications, contributing significantly to the academic and research landscape at one of Europe's oldest and most prestigious universities. Faculty of Chemistry, University of Vienna Department of Biological Chemistry Active research leader with numerous ongoing projects Significant publication record spanning multiple disciplines Professor Becker's research primarily focuses on protein chemistry, particularly post-translational modifications and their role in protein function and dysfunction. His work spans multiple interconnected areas including ubiquitination, protein aggregation, prion protein behavior, and biomimetic approaches to protein analysis. His research has significant implications for understanding neurodegenerative diseases and developing novel therapeutic approaches. The fingerprint analysis of his work shows strong connections to biochemistry, molecular biology, and chemistry, with particular emphasis on cysteine chemistry, glycosylation, and amino acid modifications. Analysis of Professor Becker's recent publications (2021-2025) reveals a consistent research trajectory focused on protein modification techniques and their biological implications. His work shows increasing sophistication in chemical biology approaches to study protein function, with particular emphasis on ubiquitination pathways and protein aggregation mechanisms. The integration of chemical synthesis methods with biological analysis represents a hallmark of his research approach. His publications span high-impact journals in biochemistry, chemical biology, and peptide science, demonstrating the interdisciplinary nature of his contributions. Professor Becker has received notable recognition for his research contributions, most prominently the Cathay Award in 2020. This award acknowledges his significant contributions to the field of protein chemistry and chemical biology. His work appears to have practical applications in therapeutic development, particularly in the areas of targeted protein degradation and immunotherapy, which likely contributed to this recognition. Cathay Award (2020) Professor Becker leads multiple significant research projects, including 'Targeted protein degradation - from small molecules to complex organelles' (2020-2024), 'Taktira: Development of an improved, low-side-effect and sustainable immunotherapy' (2019-2023), and 'Structure Zoom: Zooming in on protein functional sites with atomic resolution' (2018-2021). These projects demonstrate substantial grant funding and collaborative research efforts across multiple institutions. His active participation in 290 recorded activities through 2025 indicates a highly engaged research program with numerous collaborators and trainees. Targeted protein degradation project (2020-2024) Taktira immunotherapy project (2019-2023) Structure Zoom project (2018-2021) Professor Becker's research environment includes a robust team of collaborators and junior researchers, as evidenced by the numerous co-authored publications and activities. His work intersects with multiple research groups studying protein function, modification, and therapeutic applications. The international collaboration network shown in his profile indicates significant engagement with researchers across multiple countries, creating a dynamic research ecosystem focused on advancing protein science and its biomedical applications.
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
Brane Grambozov is a Clinical Professor in the Department of Radiotherapy and Radiation Oncology at the Medical University of Vienna. His research focuses on oncology, radiation therapy, and immunotherapy, particularly in lung cancer treatment and molecular mechanisms of non-small cell lung cancer (NSCLC). He has contributed to studies on Durvalumab's impact on survival outcomes and radiation dose escalation strategies in NSCLC Stage III patients through the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). Education: Not explicitly stated. Research interests include immunotherapy efficacy, radiation dosimetry, and biomarkers in oncology. His work emphasizes clinical trials and real-world data analysis to improve treatment outcomes and reduce toxicities like pneumonitis. He has collaborated with teams like the ALLSTAR Group and contributed to interdisciplinary studies involving radiotherapy planning and molecular biology. Key awards include the 2022 Platz Research Prize from the Austrian Society for Radiation Oncology. His advising/grant activities are not detailed but reflect contributions to lung cancer research through institutional and collaborative efforts. Labs/teams: Collaborations with the ALLSTAR Group and involvement in multidisciplinary oncology research networks.
Martin Fromm is a Professor of Clinical Pharmacology and Toxicology at Friedrich-Alexander University Erlangen-Nürnberg, where he has served as Director of the Institute of Experimental and Clinical Pharmacology and Toxicology since 2004. His career includes prior roles as Acting Professor (2002–2004), Group Leader (1999–2002), and postdoctoral fellowships at the Dr. Margarete-Fischer-Bosch Institute (1992–1996) and Vanderbilt University (1997–1999). Research Focus: Mechanisms of variable drug effects, drug transporters, medication safety, and biomarker development for transporter-mediated drug interactions. Publications: Over 170 original articles and 49 reviews with an h-index of 76 (24,000+ citations). Leadership: Chair of the University Hospital Erlangen's drug utilization committee and steering board of the Center of Clinical Studies. Scientific Awards: Top 3% Highly Cited Researcher (AD Scientific Index 2022–2024) Top 2% Highly Cited Researcher (Stanford List 2023) MSD Health Award (2021) Paul-Martini-Award (2001) Presidential Trainee Award (1998) Research Trends: His recent work integrates metabolomics, machine learning (LC-MS methods), and clinical studies to enhance medication safety in oncology and geriatrics. Earlier studies focus on transporter proteins (e.g., OCT2, MATE1, P-glycoprotein) and their role in drug absorption, metabolism, and interactions. Grants & Collaborations: Funded by DFG, BMBF, BMG, and Deutsche Krebshilfe. Active in ethics committees and clinical pharmacology societies.
Zhiming Cai is a Visiting Professor at the National Cancer Institute (NCI) and holds multiple leadership roles in China, including President of Shenzhen Medical Association, Deputy Director of Carlson International Oncology Center at Shenzhen University, and Director of the Guangdong Key Laboratory of Systemic Biology and Synthetic Biology in Genitourinary Oncology. As an Outstanding Principal Investigator at the Chinese Academy of Science's Institute of Synthetic Biology, he leads groundbreaking research in cancer genomics and synthetic biology. Doctor Philosophiae Honoris Causa, The National Academy of Science of Ukraine Fellow, American Institute for Medical and Biological Engineering (AIMBE) His research focuses on synthetic biology applications for cancer therapy , including engineered cell treatments and artificial gene circuits for tumor targeting. Notable work includes the "Remodeling Tumor Suppressor Theory" and CRISPR-based signal transduction systems that earned recognition from Nobel laureates and top-tier journals. With over 330 publications and an H-Index of 36, Cai's work has appeared in Nature , Cell , and European Urology . His research team has successfully treated over 200 advanced tumor patients using synthetic biology approaches, demonstrating clinical translation of cutting-edge technology. Guangdong Medical Natural Science Award (First Class) May 1st Labor Medal (China's highest worker award) State Council Special Allowance Expert National Model Worker International Genetically Engineering Machine Competition Gold Award Cai directs multiple high-profile research institutions including the National Tumor Genome Application Engineering Laboratory and the Academic Committee of the National and Local Joint Medical Synthetic Biology Engineering Laboratory. His work bridges basic research with clinical applications in genitourinary oncology through systematic biology approaches.
Sabine Glasl-Tazreiter is a Lecturer at the University of Vienna's Faculty of Life Sciences , specifically within the Department of Pharmaceutical Sciences and its Division of Pharmacognosy . Her office is located in room 2E 412 on the 4th floor at Josef-Holaubek-Platz 2, Vienna, Austria (1090). Contact details include telephone number +43-1-4277-55207 and email sabine.glasl@univie.ac.at . Principal research focus: Phytochemistry & Biodiscovery Specialization: Secondary metabolites from ethnomedicinally used plants across Europe, Mongolia, and Latin America Key techniques: Isolation of bioactive compounds, structural elucidation, pharmacological evaluation Quality control expertise: Macroscopic/microscopic identification, chemical analytics Recent publications highlight her work in: 2024 - Development of the VOLKSMED Database for Austrian folk medicine wound healing plants 2025 - Advanced mucociliary clearance research in respiratory systems 2023 - Innovations in optoacoustic imaging technology 2019 - Structure-function analysis of phycobiliproteins for medical imaging 2017 - Phytochemical characterization of Latin American antidiabetic plants
Ulrich Lächelt is an Assistant Professor in the Department of Pharmaceutical Sciences at the Faculty of Life Sciences. His research focuses on nanoparticle technology, drug delivery systems, and gene therapy, with a particular emphasis on CRISPR/Cas9 genome editing and RNA-based therapeutics. He leads a project on nanoformulations of prime editing ribonucleoproteins (2025–2029), aiming to advance precision medicine. His work contributes to UN Sustainable Development Goals, particularly in health and innovation. Research Interests: Nanoparticle design and material science CRISPR/Cas9 delivery systems siRNA and mRNA therapeutic formulations Cancer-targeted drug delivery Biomedical engineering applications Publications (2025–2023): Highlighted studies include dual pH-responsive CRISPR delivery systems and accelerated endosomal escape mechanisms. His work spans 40+ peer-reviewed articles, with recent trends focusing on xenopeptide carriers and tumor-targeted therapies. Grants & Projects: Current research funding includes a nanoformulations project (2025–2029). He actively collaborates on international initiatives, with recent presentations at global conferences on CRISPR delivery and gene editing strategies. Labs/Teams: Involved in interdisciplinary teams developing novel drug delivery platforms and screening tools for prime editor RNPs.
Prim. Clin. Assoc. Prof. PD Dr. Dietmar Dammerer, MSc PhD is the head of the Clinical Department of Orthopaedics and Traumatology at Krems University Hospital, affiliated with Karl Landsteiner Private University of Health Sciences. He has been in this role since February 2022, leading the merger of orthopedics and traumatology into a unified clinical department. A dual-trained specialist, he is recognized for his expertise in endoprosthetics and tumor orthopedics, and actively promotes interdisciplinary collaboration and team-based medicine. His educational background includes a PhD in Musculoskeletal Sciences (2015), an MSc in Advanced Orthopaedics and Traumatology (2017), and board certification in both orthopedics and traumatology (2017, 2018), culminating in habilitation in 2019. He has received prestigious Traveling Fellowships from the European Hip Society and European Musculo-Skeletal Oncology Society. Dietmar Dammerer’s research focuses on orthopedic oncology, joint reconstruction, biomechanics, and minimally invasive surgery. His work emphasizes the integration of clinical inquiry with research to improve patient outcomes. Recent publications analyze pelvic sarcoma reconstruction, spinal metastases, cartilage repair techniques, and health disparities in sarcoma care. His 15 most recent articles reflect a strong trend in musculoskeletal oncology, surgical biomechanics, and evidence-based orthopedic practice, with frequent use of systematic reviews, retrospective studies, and multicenter collaborations. Topics include implant performance, surgical safety, and global access to specialized care. Scientific awards include: Traveling Fellow Stipendium from the European Hip Society (2018) Traveling Fellow Stipendium from the European Musculo-Skeletal Oncology Society (2020) He is deeply committed to mentoring and team development, emphasizing that medical success is measured by the success of one’s colleagues. He leads a research-active department that hosts international observers, conducts training courses for physicians across Europe, the Middle East, and Africa, and maintains a high rate of peer-reviewed publication. The department collaborates closely with the Departments of Biomechanics and Anatomy and Developmental Biology, reflecting a multidisciplinary research approach.
Dr. Quirin Thomas Simon Vogel is a Senior Lecturer at the Department of Statistics, University of Klagenfurt. He previously held postdoctoral positions at the Technical University of Munich, New York University Shanghai, and served as an Interim Professor at Ludwig-Maximilians University of Munich. His research bridges probability theory with statistical mechanics and algorithmic applications. Current role: Senior Lecturer (2025) Previous roles: Postdoc (TUM, NYU Shanghai), Interim Professor (LMU Munich) His research focuses on: Random walks and their geometric/stochastic properties Randomized algorithms with applications in statistical models Quantum-inspired probabilistic systems (e.g. interacting bosonic loop soups) Large deviation theory for complex systems Percolation and phase transitions in particle models The articles reflect trends in probability theory, mathematical physics, and algorithmic applications. Key topics include high-dimensional percolation, Bose gas models, neural network theory, and stochastic geometry. The work combines rigorous mathematical analysis with interdisciplinary applications in physics and computer science. Scientific awards and functions cannot be determined from the provided data, as they describe other researchers. The department's research activities include projects on statistical learning, quantum models, and algorithmic probability, though Vogel's direct involvement in these specific funded projects isn't explicitly stated.
Benedikt Warth is a Full Professor for Food Chemistry and Exposome Research at the Department of Food Chemistry and Toxicology, Faculty of Chemistry, University of Vienna (since 2022). He coordinates the Austrian node of the ESFRI research infrastructure EIRENE and leads the 'Global Exposomics and Biomonitoring Laboratory' since 2017. His work bridges chemistry and toxicology, focusing on exposomics and metabolomics to assess chemical exposure and its health impacts. Education: PhD in Analytical Chemistry (2012), Master’s in Biotechnology (2009), Bachelor’s in Food Science and Biotechnology (2007) Research interests center on exposomics , metabolomics , and analytical chemistry , particularly for environmental and food-related toxicants. Recent articles highlight advancements in mass spectrometry for exposome-scale analysis, combining targeted and non-targeted approaches, and exploring chemical interactions (e.g., xenoestrogens, mycotoxins, flame retardants) in biological systems. Key trends in his publications include: Development of hybrid LC-MS methods (targeted/untargeted) for sensitive exposomics Integration of AI and cognitive computing for pathway analysis Global biomonitoring of mycotoxins and xenobiotics in vulnerable populations Standardization frameworks for non-targeted analysis (SRT) Notable awards include the 2025 Chemical Research in Toxicology Young Investigator Award , Brigitte Gedek-Science Award , and multiple grants (ERC Consolidator, Erwin-Schrödinger Fellowship). He has delivered over 20 invited talks on exposomics, including sessions at ACS Fall Meetings and international conferences. His laboratory's projects span: Breast cancer exposomics (linking environmental exposures to disease onset) High-throughput sample preparation for exposome-wide studies Systems toxicology of chemical mixtures (e.g., flame retardants, mycotoxins) Development of global metabolomic assays for toxicity prediction
Jan-Michael Peters is a leading academic affiliated with the Research Institute of Molecular Pathology (IMP) , Vienna, Austria. He has held pivotal roles including Scientific Director (2013–present) , Scientific Deputy Director (2011–2012) , and Senior Scientist (2002–2010) . His academic journey includes a Ph.D. in Cell Biology (1991) from the University of Heidelberg and postdoctoral work at Harvard Medical School and the German Cancer Research Center. 1985 : Prediploma in Biology, University of Kiel 1988 : Diploma in Biology, University of Heidelberg 1991 : Ph.D. in Cell Biology, University of Heidelberg His research focuses on cell cycle regulation , chromosome biology , mitosis , and ubiquitin-dependent proteolysis , contributing to developmental biology and molecular mechanisms. Notable scientific accolades include the Wittgenstein Prize (2011) , EMBO Young Investigator Award (2001) , and Mendel Lecture (2008) . He has been a member of the Austrian Academy of Sciences since 2012.
Peer Bork is a Professor at the European Molecular Biology Laboratory (EMBL) in Heidelberg, where he serves as Strategic Head of Bioinformatics and co-head of the Structural and Computational Biology Unit. He also holds honorary professorships at the University of Würzburg (Germany) and Fudan University (China). Educational background: PhD in Biochemistry (1990) Habilitation in Theoretical Biophysics (1995) Research interests span bioinformatics , systems biology , and microbiome analysis , focusing on functional prediction, comparative genomics, and data integration. His work explores global patterns in microbial communities, including enterotypes, drug-microbiome interactions, and planetary-scale gene fluxes. Scientific impact includes over 550 publications (70+ in Nature , Science , and Cell ) and groundbreaking discoveries like the human gut enterotypes and microbiome-based cancer biomarkers . Key projects include the SPIRE microbiome resource and the TARA Oceans expedition . Honors and leadership: EMBO member (2000) Nature Creative Mentoring Award (2008) ERC Advanced Investigator Grants (2011, 2015) Leopoldina member (2014) Honorary doctorate (University of Utrecht, 2017) Co-founder of 5 biotech companies Collaborative networks include partnerships with institutions in Berlin (Max-Delbrück-Center), Würzburg (Germany), and Shanghai (China), as well as global initiatives like the TREC expedition for environmental microbiome analysis.
Lambertus (Bart) Kiemeney is a Professor of Cancer Epidemiology and Chair of the Department for Health Evidence at Radboud University Medical Center (Radboudumc). As Scientific Director of the Radboud Institute for Health Sciences since 2012, he leads one of Radboudumc’s three major research institutes. His career spans clinical epidemiology, genetic epidemiology, and urological cancer research, with over 500 peer-reviewed publications and 25 book chapters. MSc in Biomedical Sciences (1988), PhD in Epidemiology (1992) from Radboud University Postdoctoral training at Johns Hopkins University and Fred Hutchinson Cancer Research Center (1992-1994) Kiemeney’s research focuses on the genetic and clinical epidemiology of bladder and prostate cancer , emphasizing genome-wide association studies (GWAS) and environmental risk factors. His work has identified key genetic loci (e.g., FGFR3, SLC14A1) and challenged assumptions about hereditary cancer screening and biomarker validity. Publications highlight his leadership in genetic epidemiology , including the first bladder cancer GWAS (2008) and large-scale replication studies (2014-2016). Trends include mechanistic research on urine concentration effects (2011), antioxidant risk factors (2012), and clinical translation of biomarkers (2015). Scientific Awards: 2014: Thomson Reuters’ “World’s Most Influential Scientific Minds” 2013: Dominique Chopin Distinguished Researcher Award (ESUR) 2012: Eminent Scholar at COMSATS Institute 2003-2004 & 2002: Multiple “Lecturer of the Year” awards 1992: Netherlands Cancer Society Fellowship 1983-1988: Cum Laude degrees in Physiotherapy and Biomedical Sciences As coordinator of the EU 7th Framework Programme project on renal cell cancer, Kiemeney has shaped international research collaborations. His work on coal tar safety (2010) resolved long-standing clinical concerns in dermatology.
